Cervical Cancer Deaths Down Following HPV Vaccine Introduction
Reductions in cervical cancer incidence, mortality in the U.S. greater for those aged 15 to 24 years than those aged 25 to 29, 30 to 39 years
Cervical Cancer
Cervical Cancer, CIN3 in Young Women Plummeted After HPV Vaccination
Fewer than expected cervical cancers, CIN3 cases seen among vaccinated cohorts after introduction of HPV immunization program in England
Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Tivdak Approved for Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 2 innovaTV 204 trial that evaluated Tivdak as monotherapy in 101 adult females with recurrent or metastatic cervical cancer.
Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
Immunotherapy Significantly Improved Survival in Recurrent/Metastatic Cervical Cancer
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
